• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    V

    Vermont Oxford Network

    EST. 1988
    197论文总数
    9,956引用总数

    论文量&引用量时间轴

    机构学者

    论文(198)

    年份
    起
    –
    止
    排序
    1Macrolides for the Prevention of Bronchopulmonary Dysplasia in Preterm Neonates
    Kristin L O'Connor, Jane Cracknell, Chris Cooper,Mark W Davies

    RATIONALE:Bronchopulmonary dysplasia (BPD) continues to be the most frequent complication of prematurity despite advances in neonatal care. It occurs from interactions between antenatal exposures, postnatal oxygen, ventilation-mediated injury as well as other postnatal injuries that induce a proinflammatory state in an immature developing lung. Macrolides, particularly azithromycin, have anti-inflammatory actions that may play a role in preventing BPD. A current review is required to investigate whether macrolide use in the highest-risk patient population, intubated and ventilated very preterm and very low-birthweight infants, have benefits that outweigh any harms when used for the prevention of BPD. OBJECTIVES:To evaluate the benefits and harms of: 1. macrolide antibiotics in the prevention of BPD in preterm neonates compared to no intervention; and 2. different subtypes of macrolides in preventing BPD in preterm neonates compared to other macrolides. SEARCH METHODS:We searched CENTRAL, MEDLINE, Embase, and trial registries. We conducted reference checking. The latest search date was June 2025. ELIGIBILITY CRITERIA:We included randomised and quasi-randomised trials in very and extremely preterm infants (less than 32 weeks' gestational age) or very and extremely low-birthweight infants (less than 1500 g), or both, requiring mechanical ventilation, and at risk of developing BPD, who received either a macrolide or placebo/no intervention. This included studies comparing macrolide versus macrolide. We excluded trials that enrolled: 1. only infants with Ureaplasma colonisation (and not all 'at risk' ventilated infants); 2. a broader group of infants, most of whom were not ventilated, who were only at risk because of their size and birthweight, and where specific outcome data for ventilated preterm infants were unobtainable. OUTCOMES:Our outcomes were BPD at 36 weeks' postmenstrual age (PMA); death before discharge; adverse effects including gastrointestinal upset, hepatic dysfunction, prolonged corrected QT interval (QTc) and cardiac arrhythmias, pyloric stenosis; and use of postnatal steroids to prevent or treat BPD prior to discharge. RISK OF BIAS:We used the Cochrane RoB 1 tool to assess risk of bias. SYNTHESIS METHODS:We synthesised results for each outcome using meta-analysis where possible, calculating risk ratios (RR) and risk difference with 95% confidence intervals (CI) for dichotomous outcomes and mean difference (MD) with 95% CI for continuous outcomes. Where MD was not calculable, we summarised the results using the Synthesis Without Meta-analysis (SWiM) method. We used GRADE to assess the certainty of evidence. INCLUDED STUDIES:We included six studies involving a total of 1108 infants providing macrolide or placebo (saline)/no intervention from 72 hours of age. Five studies (1033 infants) investigated the effects of intravenous azithromycin compared to placebo. The included studies were conducted in high- and upper-middle-income countries. Studies varied in the i) macrolide prescribed (azithromycin (five studies) and erythromycin (one study)) and ii) duration of intervention (three days to six weeks). All participants were very preterm and very low-birthweight infants requiring intubation and ventilation at the time of randomisation. SYNTHESIS OF RESULTS:We judged all six studies as at low risk of bias for most domains; one study was at unclear risk of bias for selective reporting, and another study was at unclear risk of bias for blinding. We downgraded the overall certainty of evidence for all outcomes due to serious or very serious concerns regarding imprecision (e.g. small number of infants, and the 95% CI including the possibility of both important benefit and harm). Any macrolide compared with placebo or no intervention Use of any macrolide may result in little to no difference in BPD at 36 weeks' PMA (RR 0.95, 95% CI 0.86 to 1.06; 6 studies, 1041 participants; low-certainty evidence). Macrolides may result in a slight reduction in death before discharge (RR 0.89, 95% CI 0.66 to 1.19; 6 studies, 1108 participants; low-certainty evidence). Macrolides may result in a reduction in gastrointestinal upset (RR 0.47, 95% CI 0.20 to 1.11; 2 studies; 91 participants; low-certainty evidence). Macrolides may result in little to no difference in hepatic dysfunction (RR 1.09, 95% CI 0.59 to 1.99; 4 studies, 391 participants; low-certainty evidence); prolonged QTc and cardiac arrhythmias (Not estimable; 2 studies, 136 participants; low-certainty evidence); and pyloric stenosis (Not estimable; 2 studies, 136 participants; low-certainty evidence). Macrolides may reduce the use of postnatal steroids to prevent or treat BPD prior to discharge (RR 0.74, 95% CI 0.54 to 1.02; 4 studies, 391 participants; low-certainty evidence). In a subgroup analysis restricted to the use of azithromycin compared with placebo (five studies), azithromycin may result in little to no difference in BPD at 36 weeks' PMA (RR 0.93, 95% CI 0.84 to 1.04; 5 studies, 966 participants; low-certainty evidence). Azithromycin may result in a slight reduction in death before discharge (RR 0.92, 95% CI 0.68 to 1.24; 5 studies, 1033 participants; low-certainty evidence). Azithromycin may result in a reduction in gastrointestinal upset (RR 0.47, 95% CI 0.20 to 1.11; 2 studies, 91 participants; low-certainty evidence). Azithromycin may result in little to no difference in hepatic dysfunction (RR 1.09, 95% CI 0.59 to 1.99; 4 studies, 391 participants; low-certainty evidence); prolonged QTc and cardiac arrhythmias (Not estimable; 2 studies, 136 participants; low-certainty evidence); and pyloric stenosis (Not estimable; 2 studies, 136 participants; low-certainty evidence). Azithromycin may reduce the use of postnatal steroids to prevent or treat BPD prior to discharge (RR 0.74, 95% CI 0.54 to 1.02; 4 studies, 391 participants; low-certainty evidence). AUTHORS' CONCLUSIONS:The use of macrolides, specifically azithromycin, for the prevention of BPD in very preterm infants at high risk of developing BPD, may result in little to no difference in BPD at 36 weeks' PMA, defined as requiring oxygen or respiratory support at 36 weeks' PMA. They may result in a slight reduction in death before discharge and a reduction in gastrointestinal upset. There may be little to no difference between groups in hepatic dysfunction, prolonged QTc and cardiac arrhythmias, or pyloric stenosis. Importantly, azithromycin may reduce the use of postnatal steroids to prevent or treat BPD prior to discharge. FUNDING:This Cochrane review had no dedicated funding. REGISTRATION:Protocol (2022) DOI: 10.1002/14651858.CD015063.

    2026The Cochrane database of systematic reviews(2026)引用:1
    引用
    AI阅读
    加入学术空间
    2Sucrose Analgesia for Venepuncture in Neonates
    Mariana Bueno,Ligyana Candido,Jiale Hu,Michelle Fiander, Jane Cracknell, Emily Xu, Jiamin Kang,Janet Yamada, Supported by the Cochrane Neonatal Group

    RATIONALE:Sucrose is, in general, safe and effective for analgesia during venepuncture in hospitalised neonates. However, there is a lack of evidence on its analgesic effects. OBJECTIVES:To evaluate the benefits and harms of orally administered sucrose for pain relief from venepuncture in preterm and term neonates compared to no intervention, standard care, and other types of analgesic interventions. SEARCH METHODS:We searched CENTRAL, MEDLINE, Ovid Embase, and trial registries in July 2025, and the China National Knowledge Infrastructure, VIP Chinese Science and Technology Periodicals, and Wanfang Data in August 2024. We checked reference lists of included studies and topic-related systematic reviews. ELIGIBILITY CRITERIA:We included randomised controlled trials (RCTs), including cross-over and cluster-RCTs, that evaluated the effects of sucrose analgesia in neonates (including term and preterm infants) up to 44 weeks' postmenstrual age undergoing venepuncture. We excluded quasi-RCTs and studies reported only as conference abstracts. We included studies administering sucrose with or without non-nutritive sucking (NNS) before, at the time of, or after venepuncture. Sucrose could be of any concentration, volume, or dose. Sucrose was compared to: no intervention, water, or standard care; skin-to-skin care; breastfeeding; feeding; NNS alone (e.g. pacifier); glucose; positioning; or topical anaesthetics. OUTCOMES:Outcomes of interest were pain intensity score, as measured by validated pain assessment scales, and adverse events. RISK OF BIAS:We used the Cochrane risk of bias tool (RoB 1). SYNTHESIS METHODS:We synthesised results for each outcome using meta-analysis where possible. We calculated risk ratios (RRs) with 95% confidence intervals (CIs) for dichotomous data (presence or absence of pain). We calculated the standardised mean difference (SMD) or mean difference (MD) for pain intensity scores (continuous outcome), each with its 95% CI. We used a fixed-effect model to combine data and quantified the impact of heterogeneity using the I² statistic. Where these methods were not feasible due to the nature of the data, we synthesised the results narratively. We used GRADE to assess the certainty of evidence for each outcome. INCLUDED STUDIES:We included a total of 29 studies, accounting for 2764 term and preterm neonates. There was a large variation in sucrose dose and concentration (from 0.1 mL/kg to 0.5 mL/kg or a set volume from 0.1 mL to 2 mL) as well as mode of administration (e.g. oral syringe, pacifier, dropper, in combination with a pacifier). Most of the studies compared sucrose to no intervention, water, or standard care (n = 17). Other comparisons include non-nutritive sucking, skin-to-skin care, breastfeeding, expressed breast milk, and other sweet solutions. SYNTHESIS OF RESULTS:Adverse events (e.g. gagging, apnoea) were not reported for any comparison. Sucrose (with or without NNS) versus no intervention, water, or standard care Sucrose with or without NNS probably reduces pain intensity scores during and 30 seconds after venepuncture compared to no intervention (SMD -0.82, 95% CI -1.02 to -0.63; 7 studies, 477 participants; moderate-certainty evidence). Sucrose with NNS reduces pain intensity scores one minute after venepuncture compared to no intervention (MD -9.15, 95% CI -9.91 to -8.39; 1 study, 100 participants; high-certainty evidence). The evidence is uncertain about the effect of sucrose without NNS on pain intensity scores two minutes after venepuncture compared to no intervention (SMD -0.99, 95% CI -1.31 to -0.68; 3 studies, 186 participants; very low-certainty evidence). Sucrose (with or without NNS) versus skin-to-skin care Sucrose without NNS may make little to no difference to pain scores during venepuncture when compared to skin-to-skin care (MD 1.49, 95% CI 0.86 to 2.12; 2 studies, 208 participants; low-certainty evidence). Pain scores after 30 seconds, one minute, and two minutes were not reported. Sucrose (with or without NNS) versus breastfeeding Sucrose probably reduces pain during venepuncture compared to breastfeeding, as measured with the Neonatal Facial Coding System (where 0 = no pain, > 0 = pain) (RR 1.38, 95% CI 1.01 to 1.88; 1 study, 103 participants; moderate-certainty evidence). Sucrose may result in little to no difference in pain compared to breastfeeding two minutes after venepuncture (RR 1.06, 95% CI 0.94 to 1.19; 1 study, 104 participants; low-certainty evidence). Pain scores after 30 seconds and one minute were not reported. Sucrose (with or without NNS) versus NNS Sucrose with NNS likely reduces pain during venepuncture compared to NNS (SMD -1.52, 95% CI -1.92 to -1.12; 2 studies, 136 participants; moderate-certainty evidence). Sucrose without NNS may not reduce pain intensity scores during venepuncture compared to NNS (MD 1.37, 95% CI 0.57 to 2.17; 2 studies, 133 participants; low-certainty evidence). Sucrose with NNS may reduce pain intensity scores one minute after venepuncture compared to NNS (MD -5.81, 95% CI -6.30 to -5.32; 2 studies, 200 participants; low-certainty evidence). Sucrose with NNS probably reduces pain intensity two minutes after venepuncture compared to NNS alone (SMD -1.30, 95% CI -1.71 to -0.89; 2 studies, 136 participants; moderate-certainty evidence). Sucrose without NNS probably results in little to no difference in pain intensity scores two minutes after venepuncture compared to NNS (MD 0.47, 95% CI -0.14 to 1.08; 1 study, 56 participants; moderate-certainty evidence). We downgraded the certainty of the evidence in several comparisons, mostly due to unclear or high risk of selection, performance, detection, and reporting bias. High heterogeneity was also detected. AUTHORS' CONCLUSIONS:Current evidence suggests sucrose probably reduces pain scores during and shortly after venepuncture compared to no intervention, water, or standard care. The evidence is very uncertain regarding the effects of sucrose compared to skin-to-skin care for analgesia during venepuncture. Compared to breastfeeding, sucrose probably results in a reduction of pain scores during venepuncture, but may result in little difference in pain scores two minutes after venepuncture. The evidence suggests sucrose with NNS probably reduces pain scores during and following venepuncture compared to NNS alone. Sucrose alone probably results in little to no difference in pain intensity scores two minutes after venepuncture compared to NNS. FUNDING:This review had no dedicated funding. REGISTRATION:Protocol available via doi/10.1002/14651858.CD015221.

    2026The Cochrane database of systematic reviews(2026)引用:1
    引用
    AI阅读
    加入学术空间
    3Enteral Lipid Supplements for the Prevention and Treatment of Parenteral Nutrition-Associated Liver Disease in Infants
    Muralidhar H Premkumar,Katie A Huff, Chris Cooper, Jane Cracknell,Mohan Pammi, supported by the Cochrane Neonatal Review Group

    RATIONALE:Enteral lipid formulations may offer benefits according to preclinical studies, but their effectiveness and safety in preventing and treating parenteral nutrition-associated liver disease (PNALD) in infants remains unknown. OBJECTIVES:To evaluate the benefits and harms of enteral lipid supplementation for the prevention and treatment of PNALD in infants. SEARCH METHODS:We searched CENTRAL, MEDLINE, Embase and trial registers, together with reference checking and contact with study authors. The latest search was in December 2024. ELIGIBILITY CRITERIA:We included parallel, randomized control trials (RCTs) in infants comparing enteral lipid supplements with either a placebo or no intervention in infants who were either at risk or who had PNALD. We excluded studies involving infants receiving enteral feeds without the need for parenteral nutrition, as they were neither at risk for PNALD, nor diagnosed with PNALD, and infants with cholestasis secondary to primary liver disease, inborn errors of metabolism, or congenital infection. OUTCOMES:Our primary outcomes were the prevention of PNALD during hospital stay and the first year of life; and resolution of PNALD during hospital stay and the first year of life. Other outcomes included feeding intolerance during the hospital stay, time to full feeds measured in days during the hospital stay, length of hospital stay in days, need for liver transplantation in the first year of life and all-cause mortality up to hospital discharge and in the first year of life. RISK OF BIAS:We used the Cochrane risk of bias 1 (RoB 1) tool to assess bias in the RCTs. SYNTHESIS METHODS:We synthesized results for each outcome using meta-analyses where possible, using random-effect models to calculate risk ratios (RRs) and risk difference (RD) with 95% confidence intervals (CIs) for dichotomous outcomes. For continuous outcomes, we calculated mean differences (MDs). If combining the data was not feasible, we summarized data narratively using Synthesis without Metaanalysis (SWiM). We summarized the certainty of evidence according to GRADE methods. INCLUDED STUDIES:We included 11 studies (2192 infants). A variety of enteral lipids were used as interventions, including algal oil, fungal oil, and fish oil, either alone or in combination. The intervention groups received: - Fish oil alone or in combination with other oils (three studies; n = 1328); - Algal oil alone or in combination with other oils (eight studies; n = 864). The comparison groups received either no intervention or other oils, such as sunflower oil, safflower oil, olive oil, or medium-chain triglyceride (MCT) oil. Most studies included preterm infants who received enteral lipid supplements while primarily on parenteral nutrition and minimal enteral nutrition, thus being considered at risk for PNALD. No studies examined enteral lipid supplementation in infants with established PNALD. SYNTHESIS OF RESULTS:Any enteral lipids compared to placebo or no treatment in infants at risk or with PNALD Enteral lipids may have little to no effect on the prevention of PNALD as measured by incidence of cholestasis during the hospital stay and in the first year of life; however, the evidence is very uncertain (RR 0.65, 95% CI 0.13 to 3.14; 3 studies, 265 participants; very low-certainty evidence). Enteral lipids may have little to no effect on feeding intolerance, but the evidence is very uncertain (RR 0.14, 95% CI 0.02 to 1.12; 4 studies, 236 participants; very low-certainty evidence). The evidence suggests that enteral lipids result in little to no difference in time taken to achieve full enteral feeds, but the evidence is very uncertain (MD -1.10, 95% CI -2.98 to 0.78; 1 study, 1273 participants; very low-certainty evidence). Enteral lipid supplementation may decrease the length of hospital stay, but the evidence is very uncertain (MD -3.44, 95% CI -6.20 to -0.68; I² not applicable; 1 study, 67 participants; very low-certainty evidence). Enteral lipids may have little to no effect on mortality up to discharge and the first year of life, but the evidence is very uncertain (RR 1.19, 95% CI 0.90 to 1.57; I² = 0%; 11 studies, 2200 participants; very low-certainty evidence). No studies reported on the resolution of PNALD during the hospital stay and in the first year of life, or the need for liver transplantation. Limitations of evidence: a wide variety of enteral lipids in both intervention and control groups made it challenging to make comparisons between the studies. Overall, the risk of selection bias was unclear to high and the certainty of evidence very low. The certainty of evidence was downgraded due to several methodological limitations, including risk of bias (allocation, blinding, and performance/detection issues), indirectness from the exclusion of high-risk infants, inconsistency in outcome definitions, and imprecision from small samples and wide confidence intervals. Incomplete reporting across studies also raised concerns about publication bias. AUTHORS' CONCLUSIONS:The evidence is very uncertain about the effect of enteral lipids on the prevention of PNALD during the hospital stay and in the first year of life. There may be little to no difference in feeding intolerance or time to achieve full enteral feeds. They may decrease the length of stay and likely do not reduce or increase mortality up to discharge or during the first year of life in infants at risk for PNALD. Due to small samples, inconsistency, and risk of bias, the available data are of very low certainty, and so we are not able to draw conclusions about the effects of enteral lipids in infants who are at risk of PNALD. No studies evaluated resolution of PNALD during the hospital stay and in the first year of life, or the need for liver transplantation. Well-designed studies are needed to evaluate the short-term and long-term effects of different enteral lipids in infants who are at risk for PNALD or have PNALD. Future studies should focus on addressing the heterogeneity of enteral lipid preparations and the inconsistency in assessment of outcomes. FUNDING:This Cochrane Review had no dedicated funding. REGISTRATION:Protocol (2021) DOI: 10.1002/14651858.CD014353.

    2026The Cochrane database of systematic reviews(2026)
    引用
    AI阅读
    加入学术空间
    4Insulin-like Growth Factor-1 for the Prevention or Treatment of Retinopathy of Prematurity
    Jennifer M Trzaski, Jane Cracknell,Katherine W Herbst, Marissa G Iverson,Graham E Quinn,David W Sink,James I Hagadorn

    RATIONALE:Retinopathy of prematurity (ROP) is a disorder of the developing retina in which abnormal proliferation of retinal blood vessels may lead to severe visual compromise or retinal detachment in infants born preterm. Insulin-like growth factor-1 (IGF-1) promotes normal retinal vessel growth in utero; however, IGF-1 levels fall substantially following preterm birth. By returning IGF-1 to in utero levels, postnatal treatment with IGF-1 may interrupt ROP pathogenesis, preventing disease or reducing its severity. OBJECTIVES:To compare treatment with IGF-1 to standard care or placebo for the prevention of retinopathy of prematurity or treatment of early retinopathy of prematurity. SEARCH METHODS:We used CENTRAL, MEDLINE, Embase, Cochrane Database of Systematic Reviews, Issue 3, 2025, in the Cochrane Library, CINAHL Plus with Full Text (EBSCOhost), Epistemonikos, clinical trials registries (US National Library of Medicine Clinicaltrials.gov, World Health Organization's International Trials Registry Platform, and ISRCTN Registry), together with reference checking and citation searching to identify studies that are included in this review. The latest search date was 10 March 2025. ELIGIBILITY CRITERIA:We considered all randomized controlled trials (RCTs), cluster-RCTs, and quasi-RCTs comparing IGF-1 with standard care or placebo for the prevention of ROP or treatment of early ROP in preterm infants. We planned to exclude cross-over randomized trials. OUTCOMES:Our outcomes of interest were: • Development of Type 1 ROP, defined as ROP requiring treatment at any time during the birth hospitalization or outpatient follow-up • Development of ROP ≥ stage 3 at any time during the birth hospitalization or outpatient follow-up • Development of ROP of any severity at any time during the birth hospitalization or outpatient follow-up • Occurrence of one or more serious adverse events (SAEs) at any time during the birth hospitalization • Mortality during the birth hospitalization • Hypoglycemia during the birth hospitalization RISK OF BIAS: We used the original Cochrane Risk of Bias 1 tool (RoB 1) to assess possible bias in the included studies. SYNTHESIS METHODS:Dichotomous data were reported using risk ratio (RR) and risk difference (RD) with 95% confidence intervals (CIs). Where possible, we synthesized results for each outcome using meta-analysis with fixed-effect models. We used GRADE to assess the certainty of evidence for each outcome. INCLUDED STUDIES:We included two studies totaling 140 participants. Both included studies were parallel-group RCTs performed between 2011 and 2016 enrolling extremely preterm infants in well-resourced settings in Europe and North America. The two published primary study references describe a two-center RCT (n = 19) and a 20-center RCT (n = 121) comparing treatment starting on the first day of life with intravenous IGF-1 (as mecasermin rinfabate) to standard care for prevention of ROP in newborn infants at 23 weeks' to 27 weeks plus six days' gestational age with follow-up through 40 weeks' postmenstrual age. SYNTHESIS OF RESULTS:Type 1 ROP/ROP requiring treatment Evidence is very uncertain regarding the effect of treatment with IGF-1 as compared to standard care/placebo for preventing development of Type 1 ROP/ROP requiring treatment (RR 0.94, 95% CI 0.38 to 2.35; P = 0.90; I2 = 0%; 2 RCTs, 116 infants; very low-certainty evidence). ROP ≥ stage 3 Evidence is very uncertain regarding the effect of treatment with IGF-1 as compared to standard care/placebo for preventing development of severe ROP (RR 1.27, 95% CI 0.61 to 2.65; P = 0.52; I2 = 0%; 2 RCTs, 116 infants; very low-certainty evidence). ROP of any severity Evidence is very uncertain regarding the effect of treatment with IGF-1 as compared to standard care/placebo for preventing development of ROP of any severity (RR 1.30, 95% CI 0.94 to 1.80; P = 0.12; I2 = 0%; 2 RCTs, 116 infants; very low-certainty evidence). SAEs during the birth hospitalization Evidence is very uncertain regarding the safety of treatment with IGF-1 as compared to standard care/placebo as reflected by the occurrence of one or more SAEs during the birth hospitalization in preterm infants (RR 1.18, 95% CI 0.94 to 1.47; P = 0.15; I2 = 65%; 2 studies, 140 infants; very low-certainty evidence). Post-hoc sensitivity analysis including only the larger RCT demonstrated an increased risk of experiencing one or more SAEs with IGF-1 compared to controls (RR 1.28, 95% CI 1.01 to 1.62, P = 0.05; RD 0.17, 95% CI 0.01 to 0.33, P = 0.04; number needed to treat for an additional harmful outcome (NNTH) 5.9; I2 = not applicable; 1 RCT, 121 infants; very low-certainty evidence). All-cause mortality during the birth hospitalization Evidence is very uncertain regarding the effect of treatment with IGF-1 as compared to standard care/placebo on all-cause mortality during the birth hospitalization in preterm infants (RR 1.69, 95% CI 0.71 to 3.99; P = 0.23; I2 = not applicable; 1 RCT, 121 infants; very low-certainty evidence). Hypoglycemia during the birth hospitalization Evidence is very uncertain regarding the safety of treatment with IGF-1 as compared to standard care/placebo as reflected by the incidence of hypoglycemia in preterm infants during the birth hospitalization (RR 1.00, 95% CI 0.62 to 1.63; P = 0.99; I2 = 0%; 2 RCTs, 140 infants; very low-certainty evidence). We assessed all results to be of very low certainty due to small total enrollment and substantial risk of bias. Both included studies had a high risk of bias in two domains. In addition, both were funded by industry. AUTHORS' CONCLUSIONS:The available data are of very low certainty, and so we are not able to draw conclusions about the effects of treatment with IGF-1 in preterm infants for preventing or treating ROP, or about its effects on risk of serious adverse events, mortality, or hypoglycemia in this population. FUNDING:This Cochrane review had no dedicated funding. REGISTRATION:Protocol available via DOI: 10.1002/14651858.CD013216.

    2026The Cochrane database of systematic reviews(2026)
    引用
    AI阅读
    加入学术空间
    5Randomized Trial of Occlusive Wrap for Heat Loss Prevention in Preterm Infants: Neurodevelopmental Outcome
    Michael J. Vincer,Maureen C. Reilly,Sunita Vohra,Valeria E. Rac,Zafira Bhaloo,Michael Dunn,Karla Ferrelli,Alex Kiss,John Wimmer,Denise Zayack,Roger Soll

    BACKGROUND: Heat loss in the delivery room in very preterm infants is associated with increased mortality, hypothermia and other adverse outcomes. The Heat Loss Preventions (HeLP) trial was designed to address these outcomes and resulted in a significant reduction of hypothermia but not a reduction in mortality. The HeLP follow-up trial was designed to determine whether application of occlusive wrap applied immediately after birth reduces adverse long-term neurodevelopmental outcomes at 18-24 months corrected gestational age in very preterm infants. STUDY DESIGN: The original HeLP trial was a randomized controlled trial of very preterm infants (< 28 weeks gestation) placed at birth in occlusive wrap (wrap group) or not placed in occlusive wrap (control group). The HeLP follow-up trial was the later assessment of these infants enrolled in the HeLP trial to determine the composite outcome of death or neurodevelopmental disability at 18-24 month corrected gestational age. RESULTS: There were 356 infants eligible for follow-up from the randomized controlled HeLP trial with a loss to follow-up of 116/356 (32.6%). The primary outcome occurred in 82/113 in the wrap group and 80/127 in the control group (p=0.149, Fisher’s exact). Because of the large loss to follow-up rate, this unadjusted odds ratio was 1.55 (95% confidence interval=0.90-2.69) while the adjusted odds ratio (adjusted for major predictors of the outcome) was virtually unchanged at 1.52 (95% confidence interval=0.83-2.80). Secondary outcomes in the wrap versus control group were: cerebral palsy 9/70 versus 5/87 (p=0.204, Fisher’s exact), Mental Developmental Index (MDI) < 85 (Bayley Scales) 30/53 versus 33/67 (p=0.538, Fisher’s exact), blindness at 0/68 versus 1/86 (p>0.999, Fisher’s exact) and deafness 5/70 versus 6/87 (p>0.999, Fisher’s exact). No difference was noted in prescription glasses, 7/70 in the wrap group versus 2/87 in the control group (p=0.085, Fisher’s exact). CONCLUSION:Use of polyethylene occlusive wrap after birth in very preterm infants was associated with similar death or long-term neurodevelopmental disability rate. Clinical Trials Registry: Clinicaltrials.gov NCT00607464

    2026BMC Pediatrics(2026)
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 198 篇论文

    合作机构(100)

    佛蒙特大学合作论文 46
    波士顿儿童医院合作论文 16
    南卡罗来纳大学合作论文 13
    斯坦福大学合作论文 11
    贝斯以色列女执事医疗中心合作论文 10
    费城儿童医院合作论文 10
    东弗吉尼亚医学院合作论文 8
    达特茅斯学院合作论文 7
    哥伦比亚大学合作论文 5
    阿尔伯塔大学合作论文 5

    机构统计